About POPPY PILL

EST. 2026 · DIRECT-TO-CONSUMER · ISO-ACCREDITED LAB TESTED

We built Poppy Pill because kratom and 7-hydroxymitragynine (7-OH) consumers deserved better — better potency, better pricing, and full transparency from the brands they trust. No underdosed tablets. No proprietary blend excuses. Just rigorously third-party tested kratom alkaloid products, honest Certificates of Analysis, and a company that stands behind every single batch it ships.

01

Why We Started

The kratom extract and 7-OH tablet market has a serious problem — it's flooded with underdosed, mislabeled, and untested products. We started Favor'd Alkz to be the exception: a direct-to-consumer brand built on verified alkaloid data and total transparency.

02

What We Sell

We specialize in 7-hydroxymitragynine (7-OH) pressed tablets — a potent alkaloid derived from the Mitragyna speciosa kratom plant. Our tablets are manufactured under strict quality controls and tested by ISO/IEC 17025-accredited laboratories.

03

Who We Serve

Adults in US states where kratom and 7-hydroxymitragynine products are legal and accessible. We take this responsibility seriously — we maintain a live regulation map, run real-time ZIP code checks, and block orders to prohibited jurisdictions.

04

How We Operate

Direct-to-consumer, online only. No middlemen. No retail markup chain. That's how we keep our prices competitive without cutting corners on alkaloid quality or lab testing. We ship every order Overnight Rush because fast service matters.

THE STORY BEHIND THE PLANT

A Botanical Legacy Centuries in the Making

From the rainforests of Southeast Asia to the center of America's opioid conversation — kratom's journey is one of tradition, science, and resilience.

Ancient Roots
ERA I · SOUTHEAST ASIA
Pre-1800s – 1921

Ancient Roots

Long before Western science gave it a name, kratom was woven into the daily life of Southeast Asian communities — chewed by farmers, brewed into tea by healers, offered to guests as a sign of respect.
Pre-1800

Traditional Use Across Southeast Asia

Thai, Malaysian, and Indonesian laborers chewed fresh Mitragyna speciosa leaves for energy and pain relief during long days of manual work.

1836

First Western Documentation

Dutch botanist Pieter Willem Korthals cataloged the plant in the Dutch East Indies, naming the genus 'Mitragyna'.

1921

Mitragynine Isolated

Scottish chemist Ellen Field first isolated mitragynine — the primary active alkaloid in kratom leaves.

Regulation & Science
Era II · 1943 – 1994
1943 – 1994

Regulation & Science

Governments moved to control kratom — not because it was dangerous, but because it competed with taxed opium. Meanwhile, scientists were quietly unlocking its chemistry.
1943

Thailand Bans Kratom

The Thai government passed the Kratom Act — but the motivation was economic. Thailand held an opium monopoly, and kratom was cutting into tax revenue. Citizens chose the cheaper, safer botanical. The state chose its bottom line.

1952

Malaysia Follows Suit

Malaysia classified kratom under the Poisons Act, making use punishable by fine and imprisonment — despite centuries of traditional use in Malaysian villages.

1965

Mitragynine Structure Solved

Researchers determined the full molecular structure of mitragynine using X-ray crystallography, opening the door to understanding exactly how kratom interacts with the body.

1994

7-Hydroxymitragynine Discovered

Scientists identified 7-OH — a minor but potent alkaloid comprising less than 2% of natural leaf content. It binds opioid receptors far more strongly than mitragynine, a discovery that would reshape the industry decades later.

The Opioid Crisis
Era III · The Crisis
1996 — 2016

The Opioid Crisis

Pharmaceutical companies promised pain relief without addiction. They were wrong. As the body count climbed past 800,000, people began searching for a way out — and many found an ancient leaf from Southeast Asia.
1996

OxyContin Launches in America

Purdue Pharma's aggressive marketing systematically dismissed addiction risks. By 2001, OxyContin generated $1 billion annually. The first wave of the opioid epidemic had begun.

2005

Kratom Reaches American Communities

Online forums and early vendors began importing dried leaf from Indonesia and Thailand. People struggling with opioid dependence shared their experiences — word spread person to person, not through marketing.

2014

American Kratom Association Founded

The AKA was established to protect consumer access and push for regulation over prohibition. They developed the Kratom Consumer Protection Act (KCPA) — model legislation now adopted across 20+ states.

2016

The People vs. the DEA

The DEA moved to emergency-schedule kratom alongside heroin and LSD. What followed was unprecedented: 142,000 petition signatures. 51 members of Congress objecting. A march on the White House. The DEA withdrew — the first time in history it reversed an emergency scheduling action.

Science & Validation
Era IV · The Science
2020 — 2023

Science & Validation

Top-tier institutions turned their attention to kratom. What they found challenged the narrative: a botanical that interacts with opioid receptors but behaves nothing like the drugs destroying communities.
2020

Johns Hopkins Landmark Survey

2,700+ kratom users surveyed: 91% used it for pain, 41% for opioid withdrawal. Of those using it for withdrawal, 35% went over a year without prescription opioids. Less than 3% met criteria for substance use disorder.

2021

Thailand Reverses Its 78-Year Ban

The country that started kratom prohibition ended it. Thailand decriminalized kratom, expunged prior convictions, and recognized its place in traditional culture. The Kratom Plant Act of 2022 regulated it as a food and herbal product.

2022

University of Florida Research Breakthrough

Dr. Christopher McCurdy's NIH-funded research confirmed mitragynine is a partial agonist — not a full agonist like fentanyl or morphine. Critically, it does not cause respiratory depression, the mechanism that kills opioid users.

2023

NIDA Clinical Observations Published

Direct observation studies found no respiratory depression at self-administered doses of 1–11g of whole-leaf material. All vital signs remained normal. No adverse events recorded.

The Road Ahead
Era V · 2024 – Present
2024 — Present

The Road Ahead

The industry stands at a crossroads. Concentrated synthetic products have triggered a new wave of regulation, while responsible producers fight for a framework that protects consumers without erasing a centuries-old botanical tradition.
2024

Concentrated 7-OH Products Flood the Market

Over 300 lab-synthesized 7-OH products appeared in the US — tablets, strips, shots, gummies. These carry a fundamentally different risk profile than natural leaf, and the regulatory response was swift.

2025

States Split: Bans vs. Regulation

While some states enacted blanket bans, 20+ states passed KCPA consumer protection laws — age restrictions, mandatory COAs, GMP standards, and alkaloid limits. Rhode Island reversed its ban entirely, choosing regulation over prohibition.

2026

The Fight for Responsible Access

The distinction between whole-leaf kratom and synthetic concentrates defines the conversation. Companies like ours believe in transparency, third-party testing, and published COAs — because the plant's reputation depends on the integrity of the people behind it.

AUTO-PLAY
WHY THIS MATTERS

Mitragynine — kratom's primary alkaloid — is a partial agonist at opioid receptors, not a full agonist like fentanyl or morphine. University of Florida and NIDA research has shown it does not cause respiratory depression — the mechanism responsible for opioid overdose deaths. This pharmacological distinction is why researchers are studying kratom as a potential tool in the fight against opioid dependence.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Historical and scientific information presented here is for educational purposes only.
RAW SIGNAL

The Honest Part

We're going to be straight with you: 7-hydroxymitragynine (7-OH) and kratom alkaloid products are not FDA-approved, and we will never claim otherwise. The FDA has not evaluated these products for safety, efficacy, or as treatments for any medical condition. We follow every applicable labeling and disclosure requirement — and we go further than the law requires because we believe informed consumers make better decisions.

We're also going to be honest about the regulatory landscape for kratom and 7-OH in the United States. It's complicated and it's changing fast. States are passing new laws, counties are enacting local bans, and the rules that apply today may be different in six months. That's why we built our kratom regulation map and live ZIP check directly into the site — so you always know your shipping status before you buy.

◆ OUR STANDARDS 5 Core Commitments
◇

ISO-Accredited Third-Party Lab Testing

Every batch of 7-OH tablets tested by ISO/IEC 17025-accredited independent labs before it ships. Full alkaloid panel, residual solvents, and elemental impurities.

VERIFIED
◇

Accurate Milligram Labeling

What's on the label is what's in the tablet. Precise 7-hydroxymitragynine dosing per unit. No hidden ingredients. No proprietary blend excuses.

COMPLIANT
◇

State-by-State Regulatory Compliance

We actively track US kratom laws and 7-OH regulations by state. We block shipments to prohibited areas automatically — no exceptions made for revenue.

ACTIVE
◇

Fair Direct-to-Consumer Pricing

No retail middlemen means you pay for premium 7-OH alkaloid quality, not the supply chain. Competitive pricing on every lot of pressed kratom tablets we ship.

GUARANTEED
◇

Real Customer Support

Mon–Fri 9AM–7PM ET, plus evenings and weekends. 24–48hr email response. No bots. No runaround.

AVAILABLE
IMPORTANT NOTICE

A Word on Compliance & Responsibility

The statements made about our 7-hydroxymitragynine tablets and kratom alkaloid products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Kratom and 7-OH products are not approved by the FDA. We take this disclaimer seriously — it is not fine print we bury; it is a fact we lead with.